FindTrial
Sign In

CIMAvax-EGF

6 trials

Sponsors

Center of Molecular Immunology (CIM), Center of Molecular Immunology

Conditions

Advanced non small cell lung cancerAdvanced non small cell lung cancer NSCLCLung cancerNon small cell lung cancer NSCLCRespiratory disorders in convalescent patients from SARS-CoV-2 infection COVID-19 SARS-CoV2

Phase 1

Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX
Active, not recruitingRPCEC00000370
Center of Molecular Immunology (CIM)Lung cancer
Start: 2021-06-01Target: 60Updated: 2026-08-10

Phase 2

CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM)
Active, not recruitingRPCEC00000375
Center of Molecular Immunology (CIM)Respiratory disorders in convalescent patients from SARS-CoV-2 infection COVID-19 SARS-CoV2
Start: 2021-12-25Target: 135Updated: 2026-08-10

Unknown Phase

CIMAvax-EGF-Platelets-Adults- Lung Cancer
RecruitingRPCEC00000284
Center of Molecular Immunology (CIM)Advanced non small cell lung cancer NSCLC
Start: 2017-12-12Updated: 2026-08-10
Phyisician Led CIMAvax-EGF lung biomarkers
Active, not recruitingRPCEC00000355
Center of Molecular Immunology (CIM)Advanced non small cell lung cancer
Start: 2021-03-12Target: 140Updated: 2026-08-10
CIMAvax-EGF in different maintenance schemes
RecruitingRPCEC00000368
Center of Molecular Immunology (CIM)Non small cell lung cancer NSCLC
Start: 2019-12-09Target: 42Updated: 2026-08-10
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT
Active, not recruitingRPCEC00000392
Center of Molecular ImmunologyAdvanced non small cell lung cancer
Start: 2021-12-01Target: 130Updated: 2026-08-10